Hammerhead ribozymes for target validation

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 2, 2002, Pages 235-247

  Goodchild, John ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Antisense oligonucleotide; Antisense RNA; Hammerhead ribozyme; Target validation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; MESSENGER RNA; NUCLEASE; RIBONUCLEASE; RIBOZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG APPROVAL; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; RAT; REVIEW; RNA CLEAVAGE;

ANIMALS; CATALYSIS; CELLS, CULTURED; CHICK EMBRYO; DROSOPHILA; DRUG DESIGN; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC VECTORS; HUMANS; MICE; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; RATS; RNA, CATALYTIC; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 0036244202     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.2.235     Document Type: Review

References (122)

1. Ribozyme structures and mechanisms
2. Hammerhead ribozymes: Biochemical and chemical considerations
3. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme
4. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target
5. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better
6. Specificity of hammerhead ribozyme cleavage
7. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA
8. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA
9. Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA
10. Hybridization of antisense reagents to RNA
11. Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers
12. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo
13. Antisense RNA gene therapy for studying and modulating biological processes
14. Generation of a mammalian cell line deficient in glucoseregulated protein stress induction through targeted ribozyme driven by a stress-inducible promoter
15. Downregulation of the CCRS β-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts
16. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA
17. Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells
18. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: Engineered tRNAs with an extended 3′ end can be exported efficiently and specifically to the cytoplasm in mammalian cells
19. Intracellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicted by secondary structures of human immunodeficiency virus Type 1 RNAs in vitro
20. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA
21. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras
22. In vitro and in vivo comparison of hammerhead, hairpin, and hepatitis delta virus self-processing ribozyme cassettes
23. Growth inhibition by a triple ribozyme targeted to repetitive B2 transcripts
24. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates
25. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias
26. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design
27. Construction of a ribozyme directed against human interleukin-6 mRNA: Evaluation of its catalytic activity in vitro and in vivo
28. Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: Production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model
29. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs
30. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer
31. Preformed ribozyme destroys tumour necrosis factor mRNA in human cells
32. Ribozyme targeting of HIV-1 LTR
33. Functional NF-IL6/CCAAT enhancer-binding protein is required for tumor necrosis factor alpha-inducible expression of the granulocyte colony-stimulating factor (CSF), but not the granulocyte/macrophage CSF human fibroblasts
34. Development of a hammerhead ribozyme against bcl-2.1. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
35. Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis
36. Modified hammerhead ribozymes as potential therapeutics
37. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene
38. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme
39. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes
40. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells
41. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
42. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein
43. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme
44. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo
45. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma
46. Specific gene suppression by engineered ribozymes in monkey cells
47. Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene
48. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors
49. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system
50. Hammerhead ribozymes against gamma-glutamylcysteine synthetase mRNA down-regulate intracellular glutathione concentration of mouse islet Biochem. cells
51. Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells
52. Ribozyme-mediated inhibition of caspase-3 activity reduces apoptosis induced by 6-hydroxydopamine in PC12 cells
53. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme
54. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library
55. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation
56. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma
57. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression
58. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells
59. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation
60. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells
61. Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells
62. Ribozyme approach identifies a functional association between the G protein beta(1)gamma(7) subunits in the beta-adrenergic receptor signaling pathway
63. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression
64. Ribozyme to human TGF-beta 1 mRNA inhibits the proliferation of human vascular smooth muscle cells
65. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC)
66. Characterization of anti-CCR5 ribozyme-transduced CD34(+) hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo
67. Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes
68. Expression of a p16(INK4a)-specific ribozyme downmodulates p16(INK4a) abundance and accelerates cell proliferation
69. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis
70. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line
71. A novel allosterically transactivated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo
72. Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin messenger RNA levels in C127I mouse cells
73. Ribozyme mediated degradation of beta-amyloid peptide precursor mrRNA in COS-7 cells
74. Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: Utility in genetic therapy of HIV-1 infections
75. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme
76. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
77. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21)
78. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme
79. Inhibition of cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides
80. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
81. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA
82. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture
83. Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygnease in porcine aortic vascular smooth muscle cells
84. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-a production by peritoneal cells in vitro and in vivo
85. Ribozyme-mediated suppression of the G protein gamma(7) subunit suggests a role in hormone regulation of adenylylcyclase activity
86. Development of a hammerhead ribozyme against BCL-2.2. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents
87. Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat platelet-derived growth factor A-chain mRNA
88. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-Positive cell line
89. Ribozyme-mediated cleavage of the BCRABL oncogene transcript; in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity
90. Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes
91. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice
92. Ribozyme-mediated attenuation of pancreatic β-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion
93. Bioactivity of anti-angiogenic ribozyme targeting Flt-1 and KDR mRNA
94. Adenovirus-mediated expression of ribozymes in mice
95. Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme
96. Generating loss-of-function phenotypes of the fushi tarazy gene with a targeted ribozyme in Drosophila
97. Efficient and specific ribozyme-mediated reduction of bovine α-lactalbumin expression in double transgenic mice
98. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy
99. Anti beta(S)-ribozyme reduces beta(S) mRNA levels in transgenic mice: Potential application to the gene therapy of sickle cell anemia
100. Attenuation of white gene expression in transgenic drosophila-melanogaster - Possible role of a catalytic antisense RNA
101. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth
102. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections
103. Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries
104. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint
105. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model - Potential application of ribozyme strategy to treat cardiovascular disease
106. Pharmacokinetics of an antiangiogenic ribozyme (Angiozyme™) in the mouse
107. Dopamine D-2 receptor ribozyme inhibits quinpirole-induced stereotypy in rats
108. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo
109. RNA interference: Listening to the sound of silence
110. Triplex-forming molecules for modulation of DNA information processing
111. Frontiers in chemical genetics
112. Antisense oligonucleotides: Promise and reality
113. The experimental use of antisense oligonucleotides: A guide for the perplexed
114. The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase
115. From bugs to drugs: Therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA
116. What affects the effect of 2′-alkoxy modifications? 1. Stabilization effect of 2′-methoxy substitutions in uniformly modified DNA oligonucleotides
117. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
118. Antisense peptide nucleic acids
119. Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation
120. Application of antisense oligonucleotides for gene functionalization and target validation
121. Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity
122. Deoxyribozymes: New players in the ancient game of biocatalysis